PDUFA VI Predictions: Industry Might Pay More, Get More From User Fees
Executive Summary
Next iteration of user fee legislation could include reducing amount of data sponsors must collect; 21st Century Cures initiative represents ‘dry run’ that could smooth agreement, Pfizer rep says.
You may also be interested in...
Lifting the ‘Breakthrough’ Veil: FDA Increases Transparency To Reduce Futile Requests
Case studies demonstrating what kinds of drugs do and don’t qualify for the expedited pathway designation will be presented at an April workshop co-sponsored by the Brookings Institution.
IRB Process Streamlining Expected In 21st Century Cures Bill
A move toward centralized institutional review board approval of study protocols could reduce clinical trial delays; House Energy and Commerce Committee also is looking at optimizing use of real-world data in the post-market setting.
BIO Wants Expanded Accelerated Approval In PDUFA Instead Of Progressive Approval
While it would not grab as much attention as creating a whole new approval pathway, BIO believes tinkering with accelerated approval to give the regulations more clarity and increase its use still could generate the change it wants at FDA.